We conducted a prospective observational study to examine immune cell distribution, with a focus on regulatory T cells, following the administration of gemigliptin, a DPP-4 inhibitor, in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease. Here, DPP4 is linked to type 2 diabetes mellitus.